Home
Features
-
Bio/Pharma’s Top 10: Biologic-Based Drugs
How do biologic-based drugs rank among leading products of the top bio/pharma companies? Which companies and products are leading the pack? DCAT Value Chain Insights takes an inside look.
-
Cancer Drugs: Market Outlook & Product Innovation
Global spending on oncology drugs, the industry’s largest therapeutic sector, is projected to reach $409 billion by 2028. What product innovation, trends, and commercialization strategies are at play?
-
SPONSORED CONTENT
OLON GROUP ANNOUNCES THE ACQUISITION OF GTP BIOWAYS GROUP
-
SPONSORED CONTENT
Global Scenario: Opportunities and Challenges in Peptides
-
SPONSORED CONTENT
Present And Future of Oncology: What Is Needed from API Suppliers?
DCAT MEMBER COMPANY COMMUNITY
-
People on the Move
Here are the latest moves and promotions of employees from the DCAT Member Company community. To submit a request to be included in People on the Move, click here. From the…
-
Women Leaders in Pharma Interview: Ilka Noack, Director of Quality Assurance and Regulatory Affairs, ChemCon GmbH
The latest interview in the DCAT Alliance for Industry Women Committee’s Women Leaders in Pharma: An Interview Series features Ilka Noack, Director of Quality Assurance and Regulatory Affairs at ChemCon GmbH. Read her…
-
Call for Applicants to Serve on the DCAT Board of Directors
The DCAT Leadership Development Committee seeks qualified DCAT Member Company Representatives to serve on its Board of Directors for the 2025 Fiscal Year (November 1, 2024, through October 31, 2025). This…
-
Women Leaders in Pharma Interview: Jennifer McCafferty, Senior Vice President, Quality Assurance and Regulatory CMC, Merck Research Laboratories
The latest interview in the DCAT Alliance for Industry Women Committee’s Women Leaders in Pharma: An Interview Series features Jennifer McCafferty, Senior Vice President, Quality Assurance and Regulatory CMC, Merck Research Laboratories. Read her…
